Key result
Streptokinase pharmacoinvasive PCI linked to worse LV systolic function vs primary PCI in STEMI.
Why the study?
The comparative efficacy of Streptokinase-based pharmacoinvasive PCI versus primary PCI on left ventricular systolic function after STEMI was not well established.
Does a streptokinase-based pharmacoinvasive strategy improve LV systolic function compared to primary PCI in patients with STEMI?
Observational (n=120)
No
Does a streptokinase-based pharmacoinvasive strategy improve LV systolic function compared to primary PCI in patients with STEMI?
Absolute Event Rate: -9% vs -11%
p-value: p=0.03
Primary PCI is associated with significantly better post-procedural left ventricular systolic function compared to a streptokinase-based pharmacoinvasive strategy in patients with STEMI.
OBJECTIVE: Tenecteplase-based pharmacoinvasive percutaneous coronary intervention (PCI) has been shown to yield outcomes comparable to primary PCI in the setting of acute ST elevation myocardial infarction (STEMI). This study was designed to compare the efficacy of pharmacoinvasive PCI following successful thrombolysis with Streptokinase versus primary PCI in patients with STEMI. METHODOLOGY: We conducted a prospective single center observational study in 120 patients with STEMI who underwent primary PCI (n=60) and Streptokinase-based pharmacoinvasive PCI (n=60). Patients with Killips class 3 or 4 at presentation, and those with evidence of failed fibrinolysis were excluded. The primary outcome was LV systolic function after angioplasty, as assessed by 2D global longitudinal strain (GLS) using speckle tracking echocardiography (STE), as well as 2D LVEF using Simpson's biplane method. RESULTS: LV systolic function after PCI was significantly lower in the pharmacoinvasive arm as compared to the primary PCI arm, both by 2D STE (GLS: -9% vs -11%; p=0.03) and 2D Simpson's biplane method (LVEF: 40.7% vs 45.1%; p=0.02). TIMI flow in the culprit vessel prior to angioplasty was better in the pharmacoinvasive arm indicating successful thrombolysis, whereas post angioplasty flow was not different. There was no in-hospital mortality in either group. There was a trend toward increased incidence of acute kidney injury in the pharmacoinvasive arm. CONCLUSION: LV systolic function is significantly better after primary angioplasty as compared to pharmacoinvasive PCI following successful thrombolysis with Streptokinase.
No takes yet. Share an insight, caveat, or question.
Paul et al. (2017) conducted an observational in Acute ST elevation myocardial infarction (STEMI) (n=120). Streptokinase-based pharmacoinvasive PCI vs. Primary PCI was evaluated on LV systolic function after angioplasty, assessed by 2D global longitudinal strain (GLS) (p=0.03). Streptokinase-based pharmacoinvasive PCI was associated with significantly lower LV systolic function compared to primary PCI in STEMI patients (GLS -9% vs -11%; p=0.03).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: